Doryx Antitrust Class Cert. Bids Fall Short, Warner Says

Law360, New York (May 29, 2013, 7:12 PM EDT) -- An antitrust lawsuit accusing Warner Chilcott PLC of attempting to stymie a generic version of the acne medication Doryx “falls woefully short” of the requirements for class action certification, the company told a Pennsylvania federal court Wednesday.

Warner Chilcott filed separate opposition filings railing against class certification bids from direct and indirect purchasers alleging the company made minor tweaks to Doryx, an antibiotic used to treat severe acne, in an effort to unfairly keep lower-priced generics off the market. The opposition filings raised a spate of...
To view the full article, register now.